Literature DB >> 17599673

Early failure of a small-diameter high-voltage implantable cardioverter-defibrillator lead.

Robert G Hauser1, Linda M Kallinen, Adrian K Almquist, Charles C Gornick, William T Katsiyiannis.   

Abstract

BACKGROUND: We have observed a higher than expected rate of Sprint Fidelis model 6949 lead failures in our practice.
OBJECTIVE: The aim of this study was to assess the performance of small-diameter Sprint Fidelis high-voltage ICD leads.
METHODS: The actuarial survival of Sprint Fidelis model 6949 leads implanted at our center was compared with that of the Sprint Quattro Secure model 6947. The United States Food and Drug Administration Manufacturers and User Facility Device Experience (MAUDE) database was searched for Sprint Fidelis models.
RESULTS: The survival of 583 Sprint Fidelis 6949 leads implanted at our center between September 2004 and February 2007 was significantly less than 285 Sprint Quattro Secure model 6947 leads implanted by us between November 2001 and February 2007 (P = .005). Six patients presented with Sprint Fidelis lead failure 4-23 months after implant. Five of the six patients experienced multiple inappropriate shocks associated with pace-sense conductor and coil fractures; the sixth patient had a fixation mechanism failure. The MAUDE search rendered reports for 679 Sprint Fidelis leads. The most frequent complaints or observations were inappropriate shocks (33%), high impedance (33%), and fracture (35%). Of 125 leads analyzed by the manufacturer, 62 involved fracture of the pace-sense conductor or coil and the high-voltage (defibrillation) conductor.
CONCLUSIONS: The Sprint Fidelis high-voltage lead appears to be prone to early failure. Its use should be limited until the failure mechanism is identified and corrected. Patients should be evaluated quarterly, and automatic lead test features should be enabled. While more data are needed, routine prophylactic replacement of intact, normally functioning Sprint Fidelis leads does not appear justified.

Entities:  

Mesh:

Year:  2007        PMID: 17599673     DOI: 10.1016/j.hrthm.2007.03.041

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  30 in total

Review 1.  Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity.

Authors:  Oussama Wazni; Bruce L Wilkoff
Journal:  Nat Rev Cardiol       Date:  2010-04-20       Impact factor: 32.419

2.  The Sprint Fidelis lead fracture story: time to come to our senses?

Authors:  P F H M van Dessel
Journal:  Neth Heart J       Date:  2010-01       Impact factor: 2.380

3.  Implantable cardioverter-defibrillator FDA safety advisories: Impact on patient mortality and morbidity.

Authors:  Jay Sengupta; Arthur C Kendig; Marlene Goormastic; Eui-Seock Hwang; Elizabeth A Ching; Roy Chung; Bruce D Lindsay; Patrick J Tchou; Bruce L Wilkoff; Mark J Niebauer; David O Martin; Niraj Varma; Oussama Wazni; Walid Saliba; Mohamed Kanj; Mandeep Bhargava; Thomas Dresing; Tyler Taigen; Christopher Ingelmo; Mohamed Bassiouny; Edmond M Cronin; Bradley Wilsmore; John Rickard; Mina K Chung
Journal:  Heart Rhythm       Date:  2012-07-03       Impact factor: 6.343

Review 4.  Considerations for cardiac device lead extraction.

Authors:  Oussama Wazni; Bruce L Wilkoff
Journal:  Nat Rev Cardiol       Date:  2016-01-29       Impact factor: 32.419

5.  Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention.

Authors:  Joshua R Silverstein; Demosthenes G Katritsis; Mark E Josephson
Journal:  Arrhythm Electrophysiol Rev       Date:  2012-09

6.  Natural history of the Sprint Fidelis lead: survival analysis from a large single-center study.

Authors:  Leonidas Tzogias; Diego Bellavia; Shivi Sharma; Thomas J Donohue; Mark H Schoenfeld
Journal:  J Interv Card Electrophysiol       Date:  2012-06       Impact factor: 1.900

Review 7.  [ICD lead defects: diagnosis and therapeutical options].

Authors:  Christian G Wollmann; Dirk Böcker; Andreas Löher; Hans H Scheld; Günter Breithardt; Rainer Gradaus
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-02-11

8.  Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures.

Authors:  Frederic S Resnic; Arjun Majithia; Sanket S Dhruva; Henry Ssemaganda; Susan Robbins; Danica Marinac-Dabic; Kathleen Hewitt; Lucila Ohno-Machado; Matthew R Reynolds; Michael E Matheny
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-04-14

9.  Ensuring medical device effectiveness and safety: a cross--national comparison of approaches to regulation.

Authors:  Daniel B Kramer; Yongtian T Tan; Chiaki Sato; Aron S Kesselheim
Journal:  Food Drug Law J       Date:  2014       Impact factor: 0.619

10.  The data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillance.

Authors:  Amit Kumar; Michael E Matheny; Kalon K L Ho; Robert W Yeh; Thomas C Piemonte; Howard Waldman; Pinak B Shah; Richard Cope; Sharon-Lise T Normand; Sharon Donnelly; Susan Robbins; Frederic S Resnic
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.